| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
20,695 |
18,339 |
$1.67M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,946 |
1,861 |
$103K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,558 |
1,451 |
$86K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,618 |
1,545 |
$85K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,432 |
1,247 |
$80K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,187 |
1,110 |
$61K |
| 99215 |
Prolong outpt/office vis |
459 |
420 |
$55K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,557 |
1,511 |
$40K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,772 |
2,655 |
$37K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
513 |
489 |
$28K |
| 83655 |
|
1,936 |
1,849 |
$27K |
| 80061 |
Lipid panel |
2,076 |
1,957 |
$26K |
| 90670 |
|
1,348 |
1,319 |
$24K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,353 |
2,224 |
$24K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
749 |
656 |
$22K |
| 99173 |
|
5,022 |
4,756 |
$18K |
| 90686 |
|
900 |
875 |
$16K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
140 |
125 |
$15K |
| 90723 |
|
847 |
823 |
$15K |
| 90647 |
|
825 |
808 |
$15K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
85 |
64 |
$13K |
| 92551 |
|
3,842 |
3,656 |
$13K |
| 96127 |
|
2,902 |
2,702 |
$11K |
| 90649 |
|
537 |
515 |
$10K |
| 90633 |
|
485 |
465 |
$8K |
| 99223 |
Prolong inpt eval add15 m |
53 |
49 |
$8K |
| 90716 |
|
420 |
403 |
$7K |
| 90680 |
|
360 |
350 |
$7K |
| 92558 |
|
910 |
879 |
$6K |
| 90707 |
|
392 |
377 |
$6K |
| 99233 |
Prolong inpt eval add15 m |
67 |
35 |
$5K |
| 81002 |
|
1,491 |
1,392 |
$4K |
| 90734 |
|
189 |
184 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
36 |
34 |
$3K |
| 99460 |
|
30 |
27 |
$2K |
| 90677 |
|
103 |
101 |
$2K |
| 99462 |
|
60 |
37 |
$2K |
| 0071A |
|
61 |
57 |
$2K |
| 99205 |
Prolong outpt/office vis |
13 |
13 |
$2K |
| 90656 |
|
84 |
82 |
$2K |
| 94010 |
|
75 |
62 |
$1K |
| 0072A |
|
29 |
29 |
$928.00 |
| 90715 |
|
39 |
37 |
$732.23 |
| 90620 |
|
42 |
39 |
$732.23 |
| 90696 |
|
61 |
50 |
$725.91 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
14 |
14 |
$566.93 |
| 90685 |
|
20 |
20 |
$395.80 |
| 81025 |
|
138 |
128 |
$386.20 |
| 86580 |
|
60 |
59 |
$342.77 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
32 |
15 |
$306.74 |
| 90672 |
|
15 |
15 |
$296.85 |
| 90700 |
|
15 |
15 |
$296.85 |
| 90671 |
|
14 |
14 |
$277.06 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
16 |
15 |
$276.90 |
| 85018 |
|
116 |
112 |
$263.78 |
| 86308 |
|
42 |
39 |
$228.00 |
| D1206 |
Topical application of fluoride varnish |
13 |
12 |
$198.00 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
13 |
13 |
$130.00 |
| 99177 |
|
13 |
12 |
$115.56 |